

SELL TP: Rs 60 | ¥ 26%

SPICEJET

Aviation

01 July 2021

Liquidity crisis, rising fuel cost dampen outlook; SELL

- SJET's Q4FY21 revenue plunged 35% YoY and it reported an adjusted net loss of Rs 2.4bn, translating to negative EPS of Rs 3.9
- We remain cautious due to the weak balance sheet (negative net worth)
 as well as growing competition amid rising fuel cost
- Maintain SELL with a revised TP of Rs 60 (vs. Rs 70) as we cut estimates owing to the pandemic-linked crisis and higher fuel costs

Mayur Milak | Nishant Chowhan, CFA researchreport@bobcaps.in

Sluggish Q4: SJET's Q4FY21 revenue plunged 35% YoY to Rs 18.8bn. RASK was at Rs 4.5 (vs. Rs 3.7 in Q3). Rising fuel costs amidst the ongoing pandemic reduced EBITDAR YoY to Rs 440mn, yielding a margin of 2.3% vs. 18.5% reported in Q3. The company reported higher other income of Rs 3.2bn (+44% QoQ) on account of expected recovery of dues from Boeing with respect to grounding of the 737 Max fleet. Adjusted net loss stood at Rs 2.4bn, translating to negative EPS of Rs 3.9. SJET intends to raise Rs 25bn through a QIP.

Strong growth outlook for FY23 but rising fuel cost a concern: Key factors that favour SJET's growth outlook over the next two years are expected improvement in capacity utilisation in the coming quarters together with reinstatement of its grounded Boeing 737 aircraft. However, rising crude oil prices could act as an impediment to earnings. Every US\$ 1 change in crude impacts the company's margins by ~60bps. We revise our FY22/FY23 fuel estimates up from US\$ 55/bbl to US\$ 65/bbl and assume a USDINR rate of Rs 73.

Earnings estimates cut on lower capacities and higher fuel costs: We cut our FY22/FY23 revenue estimates by 27%/11% owing to the pandemic-linked crisis and lowering of available capacities. Also, higher fuel costs would weigh on profitability, leading to EPS revision to -Rs 6 for FY22 (-Rs 2 earlier) and Rs 4.8 for FY23 (Rs 11 earlier). Post revision, our FY23 revenue estimates are at par with consensus. However, we remain 25% lower on EBITDA as we build in lower operating efficiency. Lower other income (assuming no further compensation receivables from Boeing) drives our PAT estimate 51% below consensus.

Availability of funds, competitive landscape remains key to survival; maintain SELL: We remain cautious on SJET due to its weak balance sheet (negative net worth) as well as lower yields amidst rising fuel costs. The key to its survival will depend on availability of liquidity (either through debt or equity) coupled with staying afloat amongst strong competition from peers who are also raising funds. We value the stock at an unchanged 4.5x FY23E EV/EBITDAR (~50% discount to INDIGO). Post estimate revision, our Mar'22 TP reduces to Rs 60 (vs. Rs 70). SELL.

Key changes

	Target	
	▼	
	▼	

Ticker/Price	SJET IN/Rs 81
Market cap	US\$ 654.0mn
Free float	40%
3M ADV	US\$ 5.0mn
52wk high/low	Rs 108/Rs 45
Promoter/FPI/DII	60%/1%/10%


Source: NSE | Price as of 30 Jun 2021

Key financials

Y/E 31 Mar	FY21P	FY22E	FY23E
Total revenue (Rs mn)	51,334	84,197	139,151
EBITDA (Rs mn)	1,743	11,648	19,837
Adj. net profit (Rs mn)	(9,983)	(3,684)	2,885
Adj. EPS (Rs)	(16.6)	(6.1)	4.8
Consensus EPS (Rs)	0.0	(4.5)	9.5
Adj. ROAE (%)	38.8	12.5	(10.9)
Adj. P/E (x)	(4.9)	(13.2)	16.9
EV/EBITDA (x)	31.9	5.1	3.0
Adj. EPS growth (%)	NA	NA	

Source: Company, Bloomberg, BOBCAPS Research | P – Provisional

Stock performance



Source: NSE





Fig 1 - Quarterly performance

(Rs mn)	Q4FY21	Q4FY20	YoY (%)	Q3FY21	QoQ (%)	FY21	FY20	YoY (%)
Total Income (A)	18,771	28,639	(34.5)	16,866	11.3	51,334	123,583	(58.5)
Operating Expenses:								
Aircraft Fuel	7,073	10,850	(34.8)	4,539	55.8	15,288	46,162	(66.9)
Employee Expenses	2,133	3,700	(42.4)	1,871	14.0	6,911	15,224	(54.6)
Other Expenses	10,359	18,117	(42.8)	8,008	29.4	27,349	57,143	(52.1)
Total Expenditure (B)	19,565	32,667	(40.1)	14,418	35.7	49,548	118,528	(58.2)
EBITDA (A-B)	(794)	(4,028)	(80.3)	2,448	(132.4)	1,786	5,055	(64.7)
EBITDAR	440	(2,702)	(116.3)	3,119	(85.9)	11,826	8,684	36.2
Other Income	3,176	1,935	64.2	2,201	44.3	9,831	8,351	17.7
Depreciation	3,138	4,557	(31.1)	3,803	(17.5)	15,580	17,339	(10.1)
EBIT	(756)	(6,651)	(88.6)	846	(189.4)	(3,963)	(3,933)	0.8
Finance Costs	1,597	1,420	12.5	1,416	12.8	6,021	5,414	11.2
PBT before excep items	(2,353)	(8,071)	(70.8)	(570)	312.9	(9,983)	(9,348)	6.8
Tax expense	-	-	-	-	-	-	-	-
Reported PAT	(2,353)	(8,071)	(70.8)	(570)	312.9	(9,983)	(9,348)	6.8
Adjusted PAT	(2,353)	(8,071)	(70.8)	(570)	312.9	(9,983)	(9,348)	6.8
Adj EPS (Rs)	(3.9)	(13.5)	(70.8)	(1.0)	312.9	(16.6)	(15.6)	6.6

Source: Company, BOBCAPS Research

Fig 2 – Sensitivity of Fuel cost to change in crude oil and forex cost as a % of sales (FY22E)

ou.oo (i :)					
(%)	USDINR				
Crude (US\$/bbl)	69.0	71.0	73.0	75.0	77.0
55.0	29.7	30.5	31.3	32.0	32.8
60.0	32.8	33.6	34.4	35.2	35.9
65.0	35.9	36.7	37.5	38.3	39.1
70.0	39.0	39.8	40.6	41.4	42.2
75.0	42.2	42.9	43.7	44.5	45.3

Source: Company, BOBCAPS

Fig 3 – Sensitivity of EBITDA margin to change in crude oil and forex (FY22E)

(%)	USDINR				
Crude (US\$/bbl)	69.0	71.0	73.0	75.0	77.0
55.0	21.7	20.9	20.1	19.3	18.5
60.0	18.6	17.8	16.9	16.1	15.3
65.0	15.4	14.6	13.8	13.0	12.2
70.0	12.3	11.5	10.7	9.9	9.1
75.0	9.2	8.4	7.6	6.8	6.0

Source: Company, BOBCAPS Research



Fig 4 – Sensitivity of EPS to change in crude oil and forex (FY22E)

(%)	USDINR				
Crude (US\$/bbl)	69.0	71.0	73.0	75.0	77.0
55.0	4.8	3.7	2.6	1.5	0.3
60.0	0.5	(0.6)	(1.8)	(2.9)	(4.0)
65.0	(3.9)	(5.0)	(6.1)	(7.3)	(8.4)
70.0	(8.2)	(9.4)	(10.5)	(11.6)	(12.7)
75.0	(12.6)	(13.7)	(14.9)	(16.0)	(17.1)

Source: Company, BOBCAPS Research

Valuation methodology

We cut our FY22/FY23 revenue estimates by 27%/11% owing to the pandemic-linked crisis and lowering of available capacities. Also, higher fuel costs would weigh on profitability, leading to EPS revision to -Rs 6 for FY22 (-Rs 2 earlier) and Rs 4.8 for FY23 (Rs 11 earlier). Post revision, our FY23 revenue estimates are at par with consensus. However, we remain 25% lower on EBITDA as we build in lower operating efficiency. Lower other income (assuming no further compensation receivables from Boeing) drives our PAT estimate 51% below consensus.

We remain cautious on SJET due to its weak balance sheet (negative net worth) as well as lower yields amidst rising fuel costs. The key to its survival will depend on availability of liquidity (either through debt or equity) coupled with staying afloat amongst strong competition from peers who are also raising funds. We value the stock at an unchanged 4.5x FY23E EV/EBITDAR (~50% discount to INDIGO). Post estimate revision, our Mar'22 TP reduces to Rs 60 (vs. Rs 70). Maintain SELL.

Fig 5 - Revised estimates

(Rs mn)	New	1	Old		Change	(%)
(KS IIII)	FY22E	FY23E	FY22E	FY23E	FY22E	FY23E
Revenues	84,197	139,151	114,883	156,146	(26.7)	(10.9)
EBITDA	11,648	19,837	18,663	25,341	(37.6)	(21.7)
OPM (%)	13.8	14.3	16	16	(14.8)	(12.2)
Adj. PAT	(3,684)	2,885	(1,457)	6,391	152.9	(54.9)
EPS (Rs)	(6.1)	4.8	(2)	11	155.4	(55.1)

Source: BOBCAPS Research

Fig 6 - Key assumptions

Parameter	FY22E	FY23E
Industry passenger traffic (mn)	85.6	141.2
SJET passenger traffic (mn)	12.6	21.8
Market share (%)	14.7	15.4
Load factor (%)	80	90
ASK (mn)	18,341	31,736
RASK (Rs)	4.59	4.38
Crude cost (US\$/bbl)	65.0	65.0
INR/USD (Rs)	73.0	73.0

Source: Company, BOBCAPS Research



Fig 7 – Peer comparison

Company		Target Brice (Pa)	Revenue CAGR FY21-23E	EPS (Rs)	Target	
Company	npany Rating Target Price (Rs	(%)	FY22E	FY23E	EV/EBITDAR (x)	
InterGlobe Aviation	ADD	2,000	73	(102)	79.4	9.0
SpiceJet	SELL	60	65	(6.1)	4.8	4.5

Source: BOBCAPS

Key risks

Key upside risks to our estimates are:

- Sharp fall in crude oil price
- Appreciation of rupee (against USD)
- Increase in market share

Sector recommendation snapshot

Stock	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
Interglobe Aviation	INDIGO IN	9	1,717	2,000	ADD
SpiceJet	SJET IN	1	81	60	SELL

Source: BOBCAPS Research, NSE | Price as of 30 Jun 2021



Financials

Y/E 31 Mar (Rs mn)	FY19A	FY20A	FY21P	FY22E	FY23E
Total revenue	91,215	123,586	51,334	84,197	139,151
EBITDA	(572)	4,964	1,743	11,648	19,837
Depreciation	2,564	17,339	15,580	15,993	16,243
EBIT	(1,687)	(3,898)	(3,962)	1,655	7,594
Net interest inc./(exp.)	(1,336)	(5,450)	(6,020)	(5,339)	(4,709)
Other inc./(exp.)	1,448	8,478	9,874	6,000	4,000
Exceptional items	602	0	0	0	(
EBT	(2,422)	(9,348)	(9,983)	(3,684)	2,885
Income taxes	0	0	0	0	C
Extraordinary items	0	0	0	0	C
Min. int./Inc. from assoc.	0	0	0	0	C
Reported net profit	(2,422)	(9,348)	(9,983)	(3,684)	2,885
Adjustments	(602)	0	0	0	
Adjusted net profit	(3,024)	(9,348)	(9,983)	(3,684)	2,885
Balance Sheet					
Y/E 31 Mar (Rs mn)	FY19A	FY20A	FY21P	FY22E	FY23E
Accounts payables	10,482	17,371	17,106	17,331	17,150
Other current liabilities	17,395	44,365	51,118	46,009	43,699
Provisions	2,787	4,762	10,423	10,423	10,423
Debt funds	11,098	4,593	7,071	8,071	4,071
Other liabilities	9,666	74,369	53.751	49,751	42,751
Equity capital	5,997	6,001	6,009	6,009	6,009
Reserves & surplus	(9,497)	(21,793)	(31,724)	(35,408)	(32,524)
Shareholders' fund	(3,500)	(15,793)	(25,715)	(29,399)	(26,514)
Total liab. and equities	47,928	129,668	113,756	102,187	91,581
Cash and cash eq.	797	402	320	1,037	2,311
Accounts receivables	1,353	2,917	3,464	3,822	4,338
Inventories	1,413	1,776	1,558	1,911	2,336
Other current assets	10,128	17,500	20,437	22,934	23,357
Investments	4	5	26	26	20,007
Net fixed assets	13,420	80,972	70,060	54,567	41,324
CWIP	15,420	00,372	0	04,507	41,024
Intangible assets	0	0	0	0	
Deferred tax assets, net	0	0	0	0	
Other assets	20,812	26,096	17,890	17,890	17,890
Total assets	47,928	129,668	113,756	102,187	91,581
Total assets	47,520	123,000	110,700	102,101	31,001
Cash Flows	EV40.4	EV00A	EV04B	EVOOF	FV00F
Y/E 31 Mar (Rs mn)	FY19A	FY20A	FY21P	FY22E	FY23E
Cash flow from operations	(3,238)	77,134	(13,776)	(11,123)	(435)
Capital expenditures	0	(84,892)	(4,667)	(500)	(3,000)
Change in investments	1,009	(1)	(21)	0	
Other investing cash flows	1,448	8,478	9,874	6,000	4,000
Cash flow from investing	2,457	(76,415)	5,187	5,500	1,000
Equities issued/Others	39	(0.505)	9	0	(4.000)
Debt raised/repaid	(1,929)	(6,505)	2,478	1,000	(4,000)
Interest expenses	(1,336)	(5,450)	(6,020)	(5,339)	(4,709)
Dividends paid	0	0	0	0	
Other financing cash flows	0	0	0	0	C
Cash flow from financing	(3,227)	(11,951)	(3,533)	(4,339)	(8,709)
Chg in cash & cash eq.	(4,008)	(11,233)	(12,123)	(9,962)	(8,144)
Closing cash & cash eq.	797	402	320	1,037	2,311

Per Share					
Y/E 31 Mar (Rs)	FY19A	FY20A	FY21P	FY22E	FY23E
Reported EPS	(5.0)	(15.6)	(16.6)	(6.1)	4.8
Adjusted EPS	(5.0)	(15.6)	(16.6)	(6.1)	4.8
Dividend per share	0.0	0.0	0.0	0.0	0.0
Book value per share	(5.8)	(26.3)	(42.8)	(48.9)	(44.1)
Valuations Ratios					
Y/E 31 Mar (x)	FY19A	FY20A	FY21P	FY22E	FY23E
EV/Sales	0.5	0.4	1.1	0.7	0.4
EV/EBITDA	(85.1)	10.1	31.9	5.1	3.0
Adjusted P/E	(16.1)	(5.2)	(4.9)	(13.2)	16.9
P/BV	(13.9)	(3.1)	(1.9)	(1.7)	(1.8
DuPont Analysis					
Y/E 31 Mar (%)	FY19A	FY20A	FY21P	FY22E	FY23E
Tax burden (Net profit/PBT)	124.9	100.0	100.0	100.0	100.0
Interest burden (PBT/EBIT)	143.5	239.8	251.9	(222.6)	38.0
EBIT margin (EBIT/Revenue)	(1.9)	(3.2)	(7.7)	2.0	5.
Asset turnover (Rev./Avg TA)	552.8	307.3	104.5	265.1	571.
Leverage (Avg TA/Avg Equity)	(8.1)	(4.2)	(2.4)	(1.2)	(0.9
Adjusted ROAE	149.0	96.9	48.1	13.4	(10.3
Ratio Analysis					
Y/E 31 Mar	FY19A	FY20A	FY21P	FY22E	FY23E
YoY growth (%)					
Revenue	17.5	35.5	(58.5)	64.0	65.3
EBITDA	NA	NA	NA	NA	70.3
Adjusted EPS	NA	NA	NA	NA	
Profitability & Return ratios (%)					
EBITDA margin	(0.6)	4.0	3.4	13.8	14.3
EBIT margin	(1.9)	(3.2)	(7.7)	2.0	5.5
Adjusted profit margin	(3.3)	(7.6)	(19.4)	(4.4)	2.
Adjusted ROAE	86.4	59.2	38.8	12.5	(10.9
ROCE	(10.2)	(9.7)	(8.1)	5.2	31.
Working capital days (days)	. ,	. ,	. ,		
Receivables	4	6	23	16	1
Inventory	6	5	12	8	(
Payables	91	110	412	199	12
Ratios (x)					
Gross asset turnover	0.2	0.9	2.2	1.3	0.6
				0.4	

Source: Company, BOBCAPS Research | Note: TA = Total Assets

0.4

1.3

(3.2)

0.3

0.7

(0.3)

0.3

0.7

(0.3)

0.4

(0.3)

(0.3)

0.5

(1.6)

(0.2)

Current ratio

Net interest coverage ratio

Adjusted debt/equity



Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): SPICEJET (SJET IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

Rating distribution

As of 30 June 2021, out of 95 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 44 have BUY ratings, 7 have HOLD ratings, 17 are rated ADD*, 4 are rated REDUCE* and 23 are rated SELL. None of these companies have been investment banking clients in the last 12 months. (*Our ADD and REDUCE ratings are in the process of being migrated to the new recommendation structure.)

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years.

BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

SPICEJET



This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.